[
  {
    "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Early detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  }
]